glp-1 generic drugs FDA Approves Hikma's Version of Diabetes Drug Victoza Personalized GLP-1 - Kin Meds
Description
Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases
Here the authors report that D-allulose triggers GLP-1 release in the gut and GLP-1R signaling on vagal afferents, counteracting arrhythmic overeating, obesity and diabetes.
Learn key deadlines, compliance, and alternatives.
Key Benefits: No injections required
Larger randomized controlled trials with long-term follow-up are necessary to confirm these associations and evaluate the risk-benefit ratios
